Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences is advancing its Phase II trial for GaRP in treating Irritable Bowel Syndrome and has introduced a new anti-obesity project aimed at creating an oral medication for weight management. The company has successfully raised capital through a placement to sophisticated investors, demonstrating its commitment to enhancing shareholder value and expanding its human health portfolio.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.